OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)

XLH is characterized by excess FGF23, hypophosphatemia, skeletal deformities, and growth impairment. For the last 40 years, XLH has been treated with multiple daily doses of oral phosphate and active vitamin D (Pi/D). Burosumab, a fully human monoclonal antibody to FGF23, has been approved by the FD...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Endocr Soc
Main Authors: Imel, Erik, Whyte, Michael, Munns, Craig, Portale, Anthony, Ward, Leanne, Nilsson, Ola, Simmons, Jill, Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Mao, Meng, Chen, Chao-Yin, Skrinar, Alison, San Martin, Javier, Glorieux, Francis
Format: Artigo
Sprog:Inglês
Udgivet: Endocrine Society 2019
Fag:
Bone and Mineral Metabolism
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555067/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR13-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker